Tag:
Amgen
Latest Headlines
Latest Headlines
Amgen gets rights to Unilife's wearable and injectable devices for $75M
Drug delivery device maker Unilife received a cash lifeline worth up to $75 million from Amgen. Amgen gains exclusive rights to the struggling York, PA, company's wearable injectors within selected drug classes and nonexclusive rights to all of Unilife's proprietary injectable delivery systems within the therapeutic areas of oncology, inflammation, bone health, nephrology, cardiovascular and neuroscience.
Unilife sells rights to its drug delivery devices to Amgen for $75M lifeline
The long-awaited grand alliance between Amgen and injectable device specialist Unilife has commenced. In return for a lifeline worth up to $75 million, Amgen gains exclusive rights to the stuggling York, PA, company's wearable injectors within selected drug classes and nonexclusive rights to all of Unilife's proprietary injectable delivery systems within the therapeutic areas of oncology, inflammation, bone health, nephrology, cardiovascular and neuroscience.
UPDATED: Amgen's osteoporosis drug 'romo' comes through with promising PhIII
Amgen scored promising Phase III data for its osteoporosis drug romosozumab, providing a pivotal win for the Big Biotech's late-stage pipeline and moving the drug one giant step toward an FDA filing later in the year. But some analysts were quick to note that the drug didn't perform as well as its main late-stage rival at Radius Health, triggering concerns about how well it may perform if it makes the leap to the market.
Google med tech play Verily to relocate to former Onyx space in South SF
Verily (formerly Google Life Sciences) demonstrated its increased independence from parent company Alphabet by leasing a new 400,000 square-foot, South San Francisco facility from Amgen.
Sandoz asks Supreme Court to nix 'exclusivity windfall' delaying biosimilar launches
Novartis' Sandoz unit rolled out its biosimilar version of Amgen's Neupogen last fall after waging a months-long battle in court--and waiting out an injunction imposed under the Biologics Price Competition and Innovation Act.
It's not just payers waiting on PCSK9 outcomes data. Doctors are holding back, too
As they rolled out disappointing news on their PCSK9 sales over the past few weeks, Amgen, Sanofi and Regeneron said that payer negotiations are bearing fruit, and once coverage kicks in, script numbers will start to build. But Express Scripts' outspoken chief medical officer, Steve Miller, doesn't see prescriptions ramping up much all year.
Amgen deploys West Pharma vials to store its injectable cancer med Imlygic
As drugs arrive in ever more formulations and the complexity of their ingredients increases, the demand for advanced storage solutions increases.
Struggling Unilife extends negotiating period with Amgen over partial takeover
Struggling injection device specialist Unilife said in an SEC filing that it needs an additional week to negotiate a deal with potential savior Amgen, which would involve the big biotech purchasing up to 19.9% of the company's stock in return for a much-needed cash infusion. If the grand alliance pans out, Amgen would also gain the preferred right of access to new drug delivery platforms and enter into a manufacturing arrangement with Unilife.
Struggling Unilife extends negotiating period with Amgen over partial takeover
Struggling injection device specialist Unilife said in an SEC filing that it needs an additional week to negotiate a deal with potential savior Amgen, which would involve the big biotech purchasing up to 19.9% of the company's stock in return for a much-needed cash infusion. If the grand alliance pans out, Amgen would also gain preferred right of access to new delivery platforms and enter a manufacturing arrangement with Unilife.
UPDATED: NICE, in reversal, OKs Amgen's Repatha while snubbing Sanofi and Regeneron's Praluent
Amgen's Repatha is in a market brawl with Sanofi and Regeneron's Praluent as the competitors rush to sew up as many OKs around the world as possible for the new-gen cholesterol fighters following their FDA approval last year within weeks of one another. Now Amgen has pulled ahead in England after the country's drug pricing watchdog has both changed course to cover Repatha for some patients, while dealing its competitors a blow with a rejection for Praluent.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- …
- next ›
- last »
